Results 251 to 260 of about 310,362 (291)

CD3ɛ Nanobody‐Engineered Extracellular Vesicles Driving In Vivo Generation of BiTE‐Secreting CAR‐Ts for Solid Tumor Therapy With Memory Response and Minimal Immunogenicity

open access: yesAdvanced Science, EarlyView.
HEK‐293T‐derived CD3ε Nb‐engineered EVs to generate dual‐targeting CAR‐T cells directly in vivo. These EVs selectively deliver CAR.BiTE transgenes into T cells and reprogramed to HLA‐G/PD‐L1‐targeting effector cells with enhanced memory and persistence.
Shi‐Wei Huang   +27 more
wiley   +1 more source

CD4+ T Cells Mediate MHC-Deficient Tumor Rejection and Endothelial Cell Reprogramming. [PDF]

open access: yesCancer Immunol Res
Kim SI   +12 more
europepmc   +1 more source

Oral Celastrol Nanomedicine Targeting Intestinal Antigen‐Presenting Cells to Effectively Mitigate Autoimmune Uveitis via Gut‐Retina Axis

open access: yesAdvanced Science, EarlyView.
Oral nanoCEL exhibits effective intestinal targeting of antigen‐presenting cells and restores the Th17/Treg balance in lymph nodes and spleen, ultimately protecting the blood‐retinal barrier by inhibiting peripheral immune cell infiltration and suppressing retinal glial cell activation.
Jinrun Chen   +13 more
wiley   +1 more source

LANA-specific CD4<sup>+</sup> effector T cells accumulate at the site of KSHV infection in humanized mice. [PDF]

open access: yesNat Commun
Böni M   +10 more
europepmc   +1 more source

Citrullinated peptides as drug candidates for rheumatoid arthritis. [PDF]

open access: yesFront Immunol
Bustos AH   +3 more
europepmc   +1 more source

IL-7: a potential next-generation adjuvant for immune cell therapies. [PDF]

open access: yesFront Immunol
Hotchkiss RS   +4 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy